Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
Authors:
Open Access
- 23 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (12) , 2827-2833
Abstract
Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C‐telopeptide (sCTX), tartrate‐resistant alkaline phosphatase 5b (TRAP‐5b), and procollagen‐1 N‐terminal telopeptide (P1NP). In a prespecified exploratory analysis of a phase 3, multicenter, double‐blind study, we evaluated the effects of denosumab (60 mg subcutaneously every 6 months for 3 years) versus placebo (1468 patients, 734 in each group) on BTM values. BTMs were measured at baseline, month 1, and predose at months 6, 12, 24, and 36 in the overall population. BTMs at month 1 are also reported for subgroups based on age (< 70 years versus ≥ 70 years), prior duration of ADT (≤ 6 months versus >6 months), and baseline BTM (≤ median versus > median BTM values). Treatment with denosumab provided a rapid and sustained decrease of BTM values compared with placebo. The median change in sCTX levels at month 1 was −90% in the denosumab group and −3% in the placebo group (p < 0.0001). The median change in TRAP‐5b levels at month 1 was −55% in the denosumab group and −3% in the placebo group (p < 0.0001). The maximal median change in P1NP was −64% in the denosumab group and −11% in the placebo group, (p < 0.0001). Significantly greater decreases in BTM for denosumab were also seen in subgroup analyses based on age, prior ADT treatment, and baseline BTM values. Suppression of bone turnover markers was consistent with marked increases in bone mineral density reported previously. © 2011 American Society for Bone and Mineral ResearchKeywords
This publication has 20 references indexed in Scilit:
- Biochemical markers of bone turnover and clinical outcomes in men with prostate cancerUrologic Oncology: Seminars and Original Investigations, 2012
- Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJournal of Bone and Mineral Research, 2010
- Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS StudyJournal of Bone and Mineral Research, 2009
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation TherapyJournal of Clinical Oncology, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Treatment-Related Osteoporosis in Men with Prostate CancerClinical Cancer Research, 2006
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998